These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 15551276)

  • 1. Initial increase in the cryoglobulin level after rituximab therapy for type II cryoglobulinemia secondary to Waldenström macroglobulinemia does not indicate failure of response.
    Ghobrial IM; Uslan DZ; Call TG; Witzig TE; Gertz MA
    Am J Hematol; 2004 Dec; 77(4):329-30. PubMed ID: 15551276
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rituximab may form a complex with IgMkappa mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virus-induced vasculitis.
    Sène D; Ghillani-Dalbin P; Amoura Z; Musset L; Cacoub P
    Arthritis Rheum; 2009 Dec; 60(12):3848-55. PubMed ID: 19950292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Observations on cryoglobulin testing: I. The association of cryoglobulins containing rheumatoid factors with manifestation of cryoglobulinemic vasculitis.
    De Rosa FG; Agnello V
    J Rheumatol; 2009 Sep; 36(9):1953-5. PubMed ID: 19531750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French Autoimmunity and Rituximab registry.
    Terrier B; Launay D; Kaplanski G; Hot A; Larroche C; Cathébras P; Combe B; de Jaureguiberry JP; Meyer O; Schaeverbeke T; Somogyi A; Tricot L; Zénone T; Ravaud P; Gottenberg JE; Mariette X; Cacoub P
    Arthritis Care Res (Hoboken); 2010 Dec; 62(12):1787-95. PubMed ID: 20740617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Should rituximab be the rescue therapy for refractory mixed cryoglobulinemia associated with hepatitis C?
    Ahmed MS; Wong CF
    J Nephrol; 2007; 20(3):350-6. PubMed ID: 17557269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Successful rituximab therapy of HCV-cryoglobulinemic vasculitis with severe ulcerative and necrotic lesions of the skin].
    Ignatova TM; Chernova OA; Gaĭdasheva EV
    Klin Med (Mosk); 2012; 90(5):64-6. PubMed ID: 22993956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Remission of refractory hepatitis C-negative cryoglobulinaemic vasculitis after rituximab and infliximab.
    Koukoulaki M; Abeygunasekara SC; Smith KG; Jayne DR
    Nephrol Dial Transplant; 2005 Jan; 20(1):213-6. PubMed ID: 15632353
    [No Abstract]   [Full Text] [Related]  

  • 8. [Waldenström macroglobulinemia associated with cutaneous lesions and type I cryoglobulinemia].
    del Olmo J; España A; Idoate MA; Panizo C
    Actas Dermosifiliogr; 2008 Mar; 99(2):138-44. PubMed ID: 18346436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of low-dose rituximab for mixed cryoglobulinemia.
    Visentini M; Granata M; Veneziano ML; Borghese F; Carlesimo M; Pimpinelli F; Fiorilli M; Casato M
    Clin Immunol; 2007 Oct; 125(1):30-3. PubMed ID: 17692572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case of mononeuritis multiplex onset with rituximab therapy for Waldenström's macroglobulinemia.
    Mauermann ML; Ryan ML; Moon JS; Klein CJ
    J Neurol Sci; 2007 Sep; 260(1-2):240-3. PubMed ID: 17537458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cryoglobulins and cryoglobulinemic vasculitis].
    Suszek D; Majdan M
    Wiad Lek; 2018; 71(1 pt 1):59-63. PubMed ID: 29558353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Acute renal failure secondary to severe type I cryoglobulinemia following rituximab therapy for Waldenström's macroglobulinemia.
    Shaikh A; Habermann TM; Fidler ME; Kumar S; Leung N
    Clin Exp Nephrol; 2008 Aug; 12(4):292-295. PubMed ID: 18288560
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Type I cryoglobulinemia with a fatal outcome].
    Echeverría B; Vitiello M; Abuchar A; Kerdel FA
    Actas Dermosifiliogr; 2011 Apr; 102(3):212-5. PubMed ID: 21376295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cryoglobulinemia].
    Cacoub P; Sène D; Saadoun D
    Rev Med Interne; 2008 Mar; 29(3):200-8. PubMed ID: 18242787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab therapy for mixed cryoglobulinemia in seven renal transplant patients.
    Basse G; Ribes D; Kamar N; Mehrenberger M; Sallusto F; Esposito L; Guitard J; Lavayssière L; Oksman F; Durand D; Rostaing L
    Transplant Proc; 2006 Sep; 38(7):2308-10. PubMed ID: 16980074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Primary macroglobulinemia presenting as multiple ulcers of the legs.
    Nishijima S; Hosokawa H; Yanase K; Asada Y; Fujinami S
    Acta Derm Venereol; 1983; 63(2):173-5. PubMed ID: 6189341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis C virus-associated type II mixed cryoglobulinemia vasculitis complicated with membranous proliferative glomerulonephritis.
    Lo KY; Chen CY; Lee CS
    Ren Fail; 2009; 31(2):149-52. PubMed ID: 19212913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-CD20 monoclonal antibody (rituximab) treatment for cryoglobulinemic vasculitis: where do we stand?
    Cacoub P; Delluc A; Saadoun D; Landau DA; Sene D
    Ann Rheum Dis; 2008 Mar; 67(3):283-7. PubMed ID: 17644544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis C virus infection, type III cryoglobulinemia, and necrotizing vasculitis.
    Brownell I; Fangman W
    Dermatol Online J; 2007 Jan; 13(1):6. PubMed ID: 17511939
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab for the treatment of type II mixed cryoglobulinemia.
    Zaja F; De Vita S; Russo D; Michelutti A; Fanin R; Ferraccioli G; Baccarani M
    Arthritis Rheum; 2002 Aug; 46(8):2252-4; author reply 2254-5. PubMed ID: 12209536
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.